Navigation Links
Pharmos Issues Letter to Shareholders
Date:9/10/2007

ally in patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor- selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-selective compounds from Pharmos' pipeline are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
2. Genomic DNA Preparation from RNAlater Preserved Tissues
3. Preparation of PCR Quality Template DNA from a Wide Range of Tissues Using InstaGene Matrix
4. Using the VersaFluor Fluorometer to Quantitate GUS Expression in Plant Tissues Bombarded With the Biolistic PDS-1000/He System
5. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
6. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
7. Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples
8. Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA)
9. Inline intellectual property raises legal issues
10. SC Johnson issues trademark warning over web offer
11. Company issues warning on outsourced software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015  Pomerantz LLP announces that a class ... ("Puma" or the "Company")(NYSE: PBYI ) and certain ... States District Court, Central District of California ... of a class consisting of all persons or entities ... May 13, 2015 inclusive (the "Class Period").  This class ...
(Date:7/2/2015)... ... ... been used in countless labs for decades. In the past, people had to go ... this was a daunting and tiring process looking at endless data tables and charts. ... the complex catalog structure. , Now thanks to FireflySci, scientists are throwing away those old ...
(Date:7/2/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today announced a litigation update. ... Verizon Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, ... District of Virginia , the Court ... certain key claims in favor of the Defendants on ...
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become ... quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers and the ... technology makes it effortless to use, while the integration of the Bluetooth speaker, alarm ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4New Cuvette E-Commerce Website Launched by FireflySci 2Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3
...
... , , , , , ... quantitative analysis of nucleic acids , and proteins has ... It includes absorption measurements in the ultraviolet and in the visibility , ... at 260 , nm and colorimetric protein determination is ...
... for Improving QPCR , , ... available QPCR machines with , ... offers better performance and ... allows researchers to quickly and easily,quantify nucleic acids for studying gene ...
Cached Biology Technology:Quantification made easy 2Quantification made easy 3Mx4000 Multiplex Quantitative PCR System*,PPP 2Mx4000 Multiplex Quantitative PCR System*,PPP 3Mx4000 Multiplex Quantitative PCR System*,PPP 4
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards (FPC) ... that it will amount to at least 340 MSEK to ... the rapid increase in market growth and orders received the ... guidance that revenue for 2015 will exceed 1,500 MSEK to ... approximately 2,200 MSEK. Due to receipt of orders ...
(Date:6/15/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces that its leading payment security technology, ... Digital Experience! @ NYC June 18th. Digital Experience! ... innovation in technology to over 300 of the top media ... Metropolitan Pavilion in New York City ...
(Date:6/10/2015)... 10, 2015 According to ... by Technology (Ultrasound, TOF, Structured Light, Stereo Vision), ... Automotive) and by Geography - Trends & Forecast ... market is expected to reach $3,319.71 Million by ... 2015 and 2020. Browse 71 market ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 33D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... step in developing a cost-effective micro sensor for long-term ... team of scientists and engineers. The new technology, ... by engineers from the National Oceanography Centre, in close ... Earth Science, which is based at the centre. ...
... Ill. , Nov. 13, 2013  Baxter International Inc. ... III clinical trial of BAX 855, an investigational extended ... The ongoing trial is aimed at assessing the efficacy ... in both prophylaxis and on-demand treatment schedules, and will ...
... PULLMAN, Wash. A class of drugs used to treat ... treating cancers and immune-related diseases, a new WSU-led study has ... have a major impact on its ability to affect specific ... "This was rather unexpected, given how relatively simple the molecules ...
Cached Biology News:New generation of micro sensors for monitoring ocean acidification 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 3Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 4Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 5Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 6Researcher finds potential new use for old drugs 2
... LC Sciences provides a comprehensive epitope ... microarrays synthesized on Paraflo microfluidic chips ... biosensor development. This comprehensive service includes ... assays using sample(s) provided by you, ...
... ,Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
... Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
... Rat Neural Stem Cell Kit with ... cells (NCSs) complete with optimized base medium ... and plate these unique cells generated from ... you need for a tissue-like mixture of ...
Biology Products: